FILGRASTIM
Severe Congenital Neutropenia
Roswell Park Cancer Instituteprotein_peptidePhase 2/3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Severe Congenital Neutropenia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Masonic Cancer Center, University of Minnesota | Phase 2/3 | BBB |
Busulphan Masonic Cancer Center, University of Minnesota | Phase 2/3 | BBB |
Cyclophosphamide University of California, San Francisco | Phase 2/3 | BB |
Romidepsin University of California, San Francisco | Phase 2 | BB |
METHOTREXATE Roswell Park Cancer Institute | Phase 2 | B |
View all 18 →
Same molecule, other indications
FILGRASTIM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →